Events

Videos

Podcasts

Articles

Gynecologic Oncology

The OncLive Gynecologic Oncology condition center page is a comprehensive resource for clinical news and expert insights on various types of gynecologic cancers, including ovarian cancer, endometrial cancer, and uterine cancer, among others. This section features news articles, interviews with gynecologic oncologists in written and video format, and podcasts that focus on unmet needs, treatment advances, and ongoing research in gynecologic cancers.

Maintenance niraparib improved progression-free survival in Chinese patients with recurrent ovarian cancer who were in a complete or partial response to platinum-based chemotherapy, meeting the primary end point of the phase 3 NORA study.
 

Maintenance Niraparib Boosts PFS in Phase 3 Study of Chinese Patients With Ovarian Cancer

Systemic Management of Ovarian Cancer: Closing Thoughts

Novel Combination Strategies in Recurrent Ovarian Cancer

Recurrent Ovarian Cancer: Novel Agents Under Investigation

Bevacizumab’s Role in Recurrent Ovarian Cancer

Recurrent Ovarian Cancer: Choosing a PARP Inhibitor

PARP Inhibition’s Role in Recurrent Ovarian Cancer

Frontline Ovarian Cancer Management: Ongoing Clinical Trials

Considerations for the JAVELIN OVARIAN 100 Study

Ovarian Cancer: Maintenance Following Frontline Bevacizumab

Ovarian Cancer: Updates to NCCN Guidelines

Treating Ovarian Cancer Based on HRD Status 

Ovarian Cancer: What is the Role of HRD Testing? 

Ovarian Cancer: Factors in Deciding on Maintenance Therapy 

 PAOLA-1: Combination Maintenance Therapy in Ovarian Cancer 

Practical Applications of PRIMA in Ovarian Cancer Management

PRIMA: Frontline Niraparib Maintenance Therapy in Ovarian Cancer 

SOLO-1: Frontline Olaparib Maintenance Therapy in Ovarian Cancer

GOG-0218: Frontline Bevacizumab in Ovarian Cancer

In our exclusive interview, Thomas Herzog, MD, discusses the FDA approval of the combination of olaparib (Lynparza) and bevacizumab (Avastin) as frontline maintenance therapy in HRD-positive advanced ovarian cancer. 

FDA Approval Insights: Olaparib/Bevacizumab in HRD+ Advanced Ovarian Cancer

The OncLive Ovarian Cancer condition center page is a comprehensive resource for clinical news and expert insights on ovarian cancer and evolving treatment approaches, including PARP inhibitors, antibody-drug conjugates, chemotherapy and more. This page features news articles, interviews in written and video format, and podcasts that focus on unmet needs, treatment advances, and ongoing research in ovarian cancer.

Ovarian Cancer

GSK-22-OSD1278 - /clinical/ovarian-cancer

Ovarian Cancer | Specialty